Comprehensive characterization of mRNA-loaded lipid nanoparticles to support formulation optimization, batch consistency, and regulatory compliance.
Lipid nanoparticles (LNPs) are the leading non-viral delivery vehicle for mRNA therapeutics and vaccines. The performance of an mRNA-LNP formulation depends critically on particle size, homogeneity, encapsulation efficiency, and colloidal stability. Rigorous analytical characterization is essential to guide formulation development, ensure batch-to-batch reproducibility, and meet quality expectations for preclinical and clinical use.
Our mRNA-LNP Formulation Analysis Service provides a dedicated analytical workflow to measure key quality attributes of your formulated LNPs. Using established biophysical and biochemical methods, we deliver quantitative data on particle size distribution, polydispersity, zeta potential, encapsulation efficiency, in vitro release kinetics, and stability under defined storage conditions. The service is designed to support formulation scientists working on mRNA vaccines, therapeutic proteins, gene editing, and other RNA-based modalities.
All analyses are performed on your supplied mRNA-LNP samples. We work with a range of lipid compositions and RNA payloads, including conventional mRNA, self-amplifying RNA, and circular RNA. Each project is scoped to your specific formulation parameters and quality target product profile (QTPP). The resulting report includes raw data, calculated values, and expert interpretation to facilitate decision-making.
Key Features
Particle Size and Zeta Potential
Particle size distribution (Z-average diameter and polydispersity index) is measured by dynamic light scattering (DLS). Zeta potential is determined by electrophoretic light scattering to assess surface charge and colloidal stability. Measurements are performed at physiologically relevant pH and formulation buffer conditions as specified.
Encapsulation Efficiency
Encapsulation efficiency is quantified using a fluorescence-based assay (e.g., RiboGreen). The method discriminates between encapsulated and free mRNA by selective fluorescence quenching in the presence of detergent. Triplicate measurements ensure precision, and results are reported as percentage of total RNA encapsulated.
In Vitro Release Profile
In vitro release kinetics are assessed under sink conditions at physiological temperature (37°C) using dialysis or ultrafiltration. Samples are collected at predetermined time points to determine the cumulative release of mRNA over time. The release profile helps evaluate formulation robustness and predict in vivo performance.
Stability Testing
Accelerated and long-term stability studies are conducted at defined storage temperatures (e.g., 4°C, 25°C, -20°C). At each time point, particle size, polydispersity, encapsulation efficiency, and visual appearance are monitored. Data are used to establish shelf-life, identify degradation mechanisms, and support formulation optimization.
Analytical Methods
Our service employs a panel of established analytical techniques tailored to mRNA-LNP characterization. The choice of methods is adapted to your specific formulation and quality attributes of interest.
Dynamic Light Scattering (DLS): Measures hydrodynamic diameter and polydispersity index. Provides rapid feedback on particle size distribution and batch homogeneity.
Electrophoretic Light Scattering (ELS): Determines zeta potential as an indicator of surface charge and electrostatic stability under different buffer conditions.
Fluorescence-Based Encapsulation Assay (RiboGreen): Quantifies encapsulation efficiency by measuring total and free mRNA using a selective dye that becomes fluorescent upon binding RNA.
HPLC-Based Purity and Integrity Analysis: Evaluates mRNA integrity and potential degradation products using size-exclusion or reversed-phase HPLC when required.
In Vitro Release Assay (Dialysis/Ultrafiltration): Profiles the release kinetics of mRNA from LNPs under physiological sink conditions over 24–72 hours.
Workflow
Each project follows a structured workflow to ensure high-quality, reproducible results. Steps are adapted to the scope of analysis and sample characteristics.
Sample Reception and Quality Check: Upon arrival, samples are logged, visually inspected (color, clarity, precipitates), and initial pH is recorded. A small aliquot is measured for background and to confirm compatibility with analytical methods.
Analytical Characterization: DLS/ELS measurements are performed in triplicate under controlled temperature. Encapsulation efficiency is determined using the RiboGreen assay. Where scoped, in vitro release studies and stability time points are initiated.
In Vitro Release and Stability: In vitro release kinetics are measured over 48–72 hours. Accelerated stability time points (e.g., 2 weeks, 4 weeks) are initiated if scoped.
Data Analysis and Reporting: Raw data are processed, QC metrics are evaluated (e.g., count rate, correlation curves, fluorescence controls). A comprehensive report is generated including summary tables, graphical plots, and an interpretation of results against specification criteria.
Customizable Report Content
Reports can be tailored to include additional endpoints such as mRNA integrity, lipid composition analysis, or accelerated stability modeling upon request. All data are provided in machine-readable formats (Excel, CSV) alongside the final PDF.
Quality Assurance
Analytical measurements are performed by trained scientists using calibrated instrumentation. DLS and zeta potential instruments are verified with NIST-traceable standards. RiboGreen assays include standard curves and control samples for each run.
All raw data are archived and traceable. Reports include detailed methods sections, instrument parameters, and statistical summaries. We comply with applicable Good Laboratory Practice (GLP) principles when required; the facility and procedures can be audited upon request.
Why Choose Us
Comprehensive Assay Panel: We offer a modular panel covering particle sizing, charge, encapsulation efficiency, release profile, and stability—saving you time from coordinating multiple vendors.
Tailored to Your Formulation: Assays are adapted to your specific lipid composition, buffer system, and RNA payload. Method parameters are optimized case by case.
Interpretative Reporting: You receive not only raw numbers but also an expert interpretation of results relative to typical benchmarks, helping you identify formulation trends and issues.
Integrated Service Experience: Our scientists are experienced with a wide range of LNP formulations and can advise on assay selection or suggest additional endpoints based on the development stage.
Backed by Creative Biogene: All projects are delivered under Creative Biogene’s ISO-aligned quality system, with dedicated project management, milestone-based reporting, and full intellectual property protection for your data.
Common Sample Types We Analyze
Our service accommodates a variety of mRNA-LNP formulation types. The analytical panel is adjusted to preserve sample integrity.
Standard mRNA-LNPs: Ionizable lipid LNPs loaded with conventional mRNA. Suitable for vaccine and protein replacement applications.
Self-Amplifying RNA (saRNA) LNPs: LNPs encapsulating replicon RNA. Requires careful handling to avoid RNA degradation; our protocols are validated for larger RNA constructs.
Surface-Modified LNPs: LNPs conjugated with antibodies, peptides, or polymers for targeted delivery. Zeta potential and size measurements are adapted to account for surface coatings.
Thermostable LNP Formulations: Lyophilized or frozen formulations intended for long-term storage. Stability testing includes reconstitution behavior and post-reconstitution characterization.
Contact Us
Whether you are optimizing a lead LNP formulation, verifying batch consistency, or building an analytical data package for regulatory submissions, the scientific team at Creative Biogene can help you design the right characterization strategy—from method selection to data interpretation. Reach out to discuss a tailored solution for your next project.
